Revumenib shortage update: What patients need to know in 2026

Is There a Revumenib Shortage in 2026?

If you're a patient taking Revumenib (brand name Revuforj) — or if you've just been prescribed it — you may be wondering whether there's a shortage. The short answer: Revumenib is not currently listed on the FDA or ASHP drug shortage databases.

But here's the longer answer: even without a formal shortage, many patients struggle to get Revumenib. That's because this is a specialty oncology drug with very limited distribution, and accessing it involves navigating a system that wasn't designed to be patient-friendly.

In this article, we'll break down the current availability picture, explain why Revumenib is hard to find, discuss costs, and share what you can do to get your prescription filled in 2026.

Is Revumenib Still Hard to Find?

Yes. Even though there's no official shortage, Revumenib remains one of the more difficult medications to access in 2026. Here's why:

• Specialty pharmacy only — Revumenib is not available at retail pharmacies. It's distributed exclusively through specialty pharmacy channels.
• Limited patient population — As an orphan drug treating rare forms of acute leukemia (KMT2A-rearranged and NPM1-mutated), the total number of patients is small, which means fewer pharmacies carry it.
• Prior authorization required — Most insurance plans require genetic testing confirmation and prior authorization before they'll cover the drug.
• High cost — At approximately $39,500 per month (wholesale acquisition cost), the financial hurdles are significant even with insurance coverage.

For a deeper look at the access challenges, read our article: Why is Revumenib so hard to find?

Why Is Revumenib Hard to Find?

There are several factors working together to make Revumenib difficult to access.

Specialty Distribution Model

Like most high-cost oncology drugs, Revumenib is distributed through a limited specialty pharmacy network. This means it's not something your neighborhood Walgreens or CVS can order. Instead, your prescription goes through a specialty pharmacy that is authorized to dispense it — and coordinating with that pharmacy can add time to the process.

Insurance Barriers

Insurance companies typically require prior authorization for Revumenib. To get approved, your oncologist needs to submit documentation showing your leukemia has a confirmed KMT2A translocation or NPM1 mutation through an FDA-authorized test. This review process can take anywhere from a few days to several weeks.

Some patients also encounter step therapy requirements, where the insurance company wants to see that other treatments have been tried before they'll approve Revumenib.

Recent FDA Approval

Revumenib was first approved in November 2024, with an expanded indication in October 2025. As a relatively new drug, the supply chain and pharmacy networks are still being built out. This can mean occasional delays in stock and fulfillment.

How Much Does Revumenib Cost in 2026?

The wholesale acquisition cost (WAC) for Revumenib is approximately $39,500 per month, which adds up to about $474,000 per year. No generic version is available.

However, most patients don't pay the full price:

• Commercial insurance — With the Revuforj Copay Program through SyndAccess, eligible commercially insured patients may pay as little as $0 per prescription. No income restrictions apply.
• Medicare and Medicaid — Government insurance programs have their own coverage pathways, though the copay program is not available for Medicare, Medicaid, TRICARE, or VA beneficiaries.
• Patient assistance — SyndAccess offers additional financial assistance programs for patients who need help with costs.

For a complete breakdown, see: How to save money on Revumenib in 2026.

Are There New Options in 2026?

The menin inhibitor landscape is evolving. While Revumenib is the only FDA-approved option as of early 2026, several other menin inhibitors are in late-stage clinical trials:

• Ziftomenib — In late-stage trials with promising results at the 600 mg dose for relapsed/refractory AML
• Bleximenib — Being developed by Johnson & Johnson for KMT2A-rearranged leukemia
• Enzomenib — In clinical development as monotherapy and in combination regimens

If one or more of these drugs gain FDA approval in 2026, it could expand the treatment options and potentially ease some of the supply pressure on Revumenib. For more details, see: Alternatives to Revumenib.

How to Find Revumenib in Stock

If you're trying to fill your Revumenib prescription right now, here's what to do:

1. Contact SyndAccess — Call 1-888-567-SYND (7963), Monday-Friday, 8 AM-8 PM ET. They can verify your insurance, connect you with a specialty pharmacy, and help with financial assistance.
2. Use Medfinder — Search medfinder.com to check which specialty pharmacies have Revumenib available near you.
3. Work with your oncology team — Your doctor's office can help push through prior authorizations and coordinate with specialty pharmacies.
4. Follow up regularly — Don't assume things are moving. Check in with your pharmacy and insurance every few days.

For detailed tips, read: How to find Revumenib in stock near you.

Final Thoughts

While Revumenib is not in a formal shortage in 2026, the reality for patients is that it can still be very hard to find and access. The combination of specialty pharmacy distribution, prior authorization requirements, and high costs creates real barriers that patients have to navigate — often while dealing with a serious cancer diagnosis.

The best thing you can do is start the process early, use the resources available to you (SyndAccess, Medfinder, your oncology team), and stay persistent. Help is available, and you don't have to figure this out alone.

For more about Revumenib, check out:

• What is Revumenib? Uses, dosage, and what you need to know
• Revumenib side effects: What to expect
• How to check if a pharmacy has Revumenib in stock